Monocytic leukemia
diseaseOn this page
Summary
Monocytic leukemia (MONDO:0004600) is a cancer and 6 clinical trials. Top therapeutic interventions include ascorbic acid and hyaluronidase (human recombinant). A subtype of leukemia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 6
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | monocytic leukemia |
| Mondo ID | MONDO:0004600 |
| DOID | DOID:8527 |
| ICD-10-CM | C93 |
| SNOMED CT | 188744006 |
| UMLS | C0598894 |
| MedGen | 109338 |
| GARD | 0024074 |
| Is cancer (heuristic) | yes |
Disease family
This is a subtype of leukemia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › leukemia › monocytic leukemia
Related subtypes (11): chronic leukemia, chronic erythremia, testicular leukemia, central nervous system leukemia, aleukemic leukemia, splenic manifestation of leukemia, childhood leukemia, myeloid leukemia, lymphoid leukemia, acute leukemia, mast cell leukemia
Subtypes (2): chronic monocytic leukemia, acute monocytic leukemia
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 6.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 2 |
| PHASE1 | 2 |
| PHASE1/PHASE2 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07292272 | PHASE2 | RECRUITING | Halt Aging in Survivors of Blood Cancers |
| NCT03613727 | PHASE2 | COMPLETED | Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients |
| NCT05282459 | PHASE1/PHASE2 | COMPLETED | Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation |
| NCT06429449 | PHASE1 | RECRUITING | Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia |
| NCT04714372 | PHASE1 | COMPLETED | FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia |
| NCT05871008 | Not specified | ACTIVE_NOT_RECRUITING | Integrated Actionable Aging Assessment for Cancer Patients Pilot |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| ASCORBIC ACID | 4 | 1 |
| HYALURONIDASE (HUMAN RECOMBINANT) | 4 | 1 |